Document:

<PAGE>

                                                                   EXHIBIT 10.13

                              EMPLOYMENT AGREEMENT

     THIS AGREEMENT is made as of the 6th day of January 2006, between
BRIDGETECH HOLDINGS INTERNATIONAL, INC., a Delaware corporation ("Employer"),
and HERBERT Y. WONG, an individual resident of the State of Texas ("Employee").

                                   WITNESSETH:

     WHEREAS, Employer and Employee desire to set forth the terms of Employee's
employment by Employer;

     NOW, THEREFORE, in consideration of the premises and the mutual covenants
and agreements herein set forth, the parties hereto agree as follows:

     1. EMPLOYMENT. Employer hereby engages and employs Employee and Employee
accepts such employment with Employer, all on the terms set forth herein.
Employee's principal duties initially shall be to serve as Chairman Emaritus and
Founder with general responsibilities to assist in strategic matters of
Employer. During his or her employment hereunder, Employee shall devote his or
her best efforts and attention on a semi full-time basis to the performance of
the duties required of Employee and shall discharge his or her duties in
accordance with the directions of the Board of Directors of Employer.

     2. CANCELLATION OF EXISTING CONTRACTS. Employer and Employee agree that any
existing employment, noncompetition, confidentiality or change-in-control
agreements will be cancelled upon the effectiveness of this Agreement.

     3. COMPENSATION.

          3.1 CASH COMPENSATION. As partial compensation for his or her services
hereunder, Employee:

               (a) shall receive an annual base salary of Two Hundred Forty
Thousand and No/100 ($240,000.00) Dollars (U.S.), prorated for any partial year
of employment and payable in equal installments in accordance with Employer's
then-current payroll practices and procedures and subject to all applicable
taxes and withholdings;

               (b) shall receive reimbursement of ordinary and necessary travel
and other expenses, subject to Employer's standard policies (including any
required approvals) and reimbursement for all cell phone and Internet access
charges;

               (c) shall be provided medical and dental coverage for Employee
and his immediate family by Employer, either through an employee benefit plan or
separate policy(s), with Employer paying one hundred (100%) percent of all
premiums on such coverages,; and

<PAGE>

               (d) shall be eligible to participate in those (i) employee
benefit plans, and (ii) incentive compensation and equity-related programs,
maintained by Employer, the latter being contingent upon recommendation of the
Chairman of the Board of Employer and approval by the Compensation Committee of
Employer's Board of Directors; provided, however, that any such incentive
compensation plan shall provide that, upon mutual pre-determined performance
goals being achieved, Employee shall receive an annual bonus in cash not less
than fifty (50%) nor more than one hundred (100%) percent of Employee's
then-current annual salary.

          3.2 EQUITY COMPENSATION. As additional compensation for his or her
services hereunder, Employee:

               (a) Shall be granted on an annual basis non-qualified or
incentive (as the parties may from time-to-time determine) options to purchase
shares of the voting capital stock of Employer, in such amounts and at such
exercise prices as may be determined from time-to-time by the Compensation
Committee of Employer's Board of Directors, and upon such terms as are set forth
in the documentation to evidence such grant; provided, however, that Employer
hereby agrees, and such documentation shall provide, that such options shall
fully vest upon the sooner to occur of (i) the third anniversary of the date of
grant, or (ii) a Change of Control (as that term is defined in Exhibit "B"
attached hereto); and

     4. CONFIDENTIALITY. Employee shall not disclose to third parties or use for
his or her own or others' benefit any Proprietary Information of Employer or any
of its subsidiaries of which he or she becomes informed during his or her
employment, whether or not such information or material is developed by him,
except as might be required to be disclosed or used by him in order to perform
the duties of his or her employment. As used herein, the term "Proprietary
Information" refers to any and all information of a confidential, proprietary or
secret nature which is or may be either applicable to or related in any way to
(a) the business, present or future, of Employer or any of its subsidiaries,
including without limitation the business of Employer, (b) the research and
development or investigations of Employer or any or its subsidiaries, or (c) the
business of any customer of Employer or any of its subsidiaries, and shall
include, but not be limited to, trade secrets, processes, formulas, data,
algorithms, source codes, object codes, documentation, flow-charts, drawings,
correspondence, know-how, improvements, inventions, techniques, concepts,
technologies, programs, designs, personnel records, marketing plans and
strategies, customer lists, pricing and bidding policies and practices, costing
information, salaries, proposals to licensors or customers, any data,
confidential information or property entrusted to Employer or any of its
subsidiaries by any licensors or customers and confidential information
concerning customers or employees of Employer or any of its subsidiaries.
Employee shall remain under this obligation of confidentiality for a period
expiring one (1) year after termination of his or her employment hereunder (or
indefinitely in the case of trade secrets) unless and until he or she is
expressly released from it in a writing signed by Employer or he or she learns
with certainty that the information or material in question has become public
knowledge.

     5. EMPLOYER'S RIGHTS TO CERTAIN DISCOVERIES, ETC. Employee shall disclose
promptly to Employer any and all concepts, inventions, improvements,
discoveries, developments, techniques, modifications, procedures, formulas,
ideas, trade secrets, innovations,

                                      -2-

<PAGE>

systems, programs, know-how or designs (collectively, the "Discoveries") related
to the business or activities of Employer that he or she conceives, develops or
reduces to practice during the time that he or she is employed by Employer.
Employee agrees that all his or her right, title and interest in such
Discoveries shall belong to Employer, in confirmation of which he or she shall
execute deeds of assignment of such right, title and interest to Employer, its
nominees, successors or assigns, whenever requested, without demanding separate
or additional compensation therefor. All of the foregoing shall be the subject
of the same confidentiality, nonuse and nondisclosure requirements as are
prescribed in Section 4 hereof. Any of the Discoveries related to the business
of Employer that Employee may reduce to practice or apply for a copyright or
patent on during the first six (6) months after termination of his or her
employment hereunder shall be presumed to have been conceived by him during the
time of such employment and as such shall belong to Employer, and the burden
shall be upon Employee, if he or she contends it was not, to prove it was not by
clear and convincing evidence.

     6. ASSISTANCE IN PROTECTING DISCOVERIES, ETC. Employee shall assist
Employer and its nominees, successors or assigns (at its or their request) in
every proper way during and following the period of his or her employment
(entirely at its or their expense) to obtain and maintain for its or their own
benefit copyrights or patents in any and all countries for all Discoveries
described in Section 5 hereof. Such assistance shall include, but not be limited
to, the execution and delivery of all lawful papers and documents of every
nature which relate to the securing and maintenance of such copyrights and
patent rights, and the performance of all other lawful acts, such as the giving
of testimony in any interference proceedings, infringement suits, or other
litigation, as may be deemed necessary or advisable by Employer or its nominees,
successors or assigns.

     7. DELIVERY OF DOCUMENTATION, ETC. Upon termination of his or her
employment, Employee shall promptly deliver to Employer any and all software,
documents, drawings, manuals, letters, notes, notebooks, reports, and copies
thereof, and all other materials of a secret or confidential nature relating to
Employer's business or activities, or relating to Employer's customers, vendors
or other business associates, that are in his or her possession or under his or
her control.

     8. COVENANTS NOT TO COMPETE WITH OR SOLICIT FROM EMPLOYER. Acknowledging
that the covenants contained in this Section 8 are part of the consideration
for, and are reasonable in light of the employment and compensation covenants of
Employer contained in this Agreement, Employee hereby covenants and agrees with
Employer that, during his or her employment with Employer and for a period
expiring one (1) year after the date of termination of such employment, that:

               (a) During the period of such employment he or she will not
directly or indirectly compete with Employer for the business of providing
products or services of any type provided by Employer during the term of this
Agreement and will not otherwise engage in Prohibited Competition (as such term
is defined in Section 8(b)), and after termination of such employment he or she
will not directly or indirectly compete with Employer for the business of
providing products or services (or derivative products or services) which were
offered or provided by Employer within one (1) year prior to the termination of
such employment within that

                                       -3-

<PAGE>

geographical area shown on Exhibit "A" attached hereto and incorporated herein
(the "Territory") nor otherwise engage in Prohibited Competition. The Territory
is hereby acknowledged by both Employer and Employee as comprising the primary
territory served by Employer and the territory in which Employer has actively
solicited customers as of the date hereof.

               (b) "Prohibited Competition" shall consist of acting as
consultant, advisor, independent contractor, officer, manager, employee,
principal, agent, trustee of any corporation, partnership, association or agent
or agency, or directly or indirectly owning more than one (1%) percent of the
outstanding capital stock of any corporation, or being a member or employee of
any partnership or any owner or employee of any other business, any of which
conducts a business in competition with Employer or any of its subsidiaries for
the duration of this noncompetition agreement as set forth herein. "Prohibited
Competition" shall also include (in addition to the foregoing):

                    (i) Accepting employment with a customer of Employer or
     Employer's affiliates with the intent or purpose of transferring business
     performed by Employer or Employer's affiliates to a department, division of
     affiliate of the customer;

                    (ii) Requesting or advising any of the customers, suppliers
     or other business contacts of Employer or Employer's affiliates to
     withdraw, curtail, cancel or not increase their business with Employer or
     Employer's affiliates; or

                    (iii) Causing or inducing, or attempting to cause or induce,
     either directly or indirectly, any employees, sales representatives,
     consultants or other personnel of Employer or Employer's affiliates to
     terminate their relationships or employment or breach their agreements with
     Employer or Employer's affiliates, whether for the purpose of accepting
     employment with Employee or any other person, firm, association or
     corporation with which Employee is associated, or otherwise, or hiring any
     employee of Employer or its affiliates within four (4) months of such
     person having left the employ of Employer or of such affiliate.

     9. INJUNCTIVE RELIEF. Employee recognizes that the breach of any of his or
her obligations under Sections 4, 5, 6, 7 or 8 hereof will give rise to
irreparable injury to Employer inadequately compensable in damages and that,
accordingly, Employer shall be entitled to injunctive relief against the breach
or threatened breach of the within undertaking, without the requirement of
posting a bond, in addition to other remedies at law or in equity which may be
available.

     10. TERM. The term of this Agreement shall begin on the effective date of
this Agreement and shall terminate on the third anniversary hereof, unless
sooner terminated by either party in the manner set forth below. Either Employer
or Employee may terminate Employee's employment at any time by giving thirty
(30) days' prior written notice to the other. In addition, Employer shall have
the right at any time to terminate Employee's employment immediately for cause.
Any action by Employer to terminate Employee's employment shall be deemed "for
cause" if:

                                       -4-

<PAGE>

               (a) Employee is unable to perform the essential functions of his
or her job, with or without reasonable accomodation, (i) as a result of the
habitual use of alcohol or drugs; or (ii) failure to perform his or her duties
after written notice of such failure;

               (b) Employee has disclosed any material secret or confidential
information of Employer or any subsidiary thereof without the consent of
Employer or has violated or disregarded any other material duties, obligations
or expected conduct as an employee of Employer;

               (c) Employee has committed any act or omitted to take any action
in bad faith and to the detriment of Employer or any affiliate thereof;

               (d) Employee has committed (i) any felony; or (ii) any
misdemeanor or other illegal conduct involving dishonesty, fraud or other
matters of moral turpitude; or

               (e) Employee has acted against, or failed or omitted to act in,
the best interests of Employer or any affiliate thereof, as determined in good
faith by the Board of Directors of Employer.

Employee's obligations under Sections 4, 5, 6, 7, 8 and 12 hereof shall survive
and continue in effect following any termination of employment.

     11. SEVERANCE. If Employer should terminate Employee's employment for any
reason other than for cause pursuant to the preceding Section 10, Employee shall
be paid an amount equal to his or her then-current monthly salary multiplied by
the number of months remaining under this agreement, which payment shall be
considered additional consideration for the noncompetition agreements set out in
Section 8 hereof. Employee shall also be paid all unpaid annual bonuses for the
remaining years under this agreement, in cash, at one hundred (100%) of the
employee's then-current annual salary.

     12. LITIGATION ASSISTANCE. Employee shall, for a period of five (5) years
after termination of his or her employment hereunder, at no cost to Employer,
unless otherwise provided herein, diligently and fully cooperate with Employer,
including testifying, answering interrogatories, being deposed, and generally
providing information and fully cooperating with the defense or prosecution of
any suit or cause of action brought by or defended by Employer based upon any
facts relating to any contact or matter which originated during Employee's
employment by Employer. Employer agrees to provide reasonable travel expenses
pursuant to its current business travel policy for Employee's assistance and
cooperation in all such actions or suits, if required. Any requests for time
away from Employee's work must be reasonably acceptable to Employee, and
Employee shall be compensated on a per diem basis based on Employee's annual
salary on the day before termination of this Agreement.

     13. ASSIGNMENT. The rights and benefits of Employee under this Agreement,
other than accrued and unpaid amounts due under Section 3 hereof, are personal
to him and shall not be assignable. Discharge of Employee's undertakings in
Sections 4, 5, 6, 7 and 8 hereof shall

                                       -5-

<PAGE>

remain an obligation of Employee's executors, administrators, or other legal
representatives or assigns.

     14. NOTICES. All notices, demands, requests, or other communications which
may be or are required to be given, served, or sent by either party to the other
party pursuant to this Agreement shall be in writing and shall be hand delivered
(including delivery by courier so long as a receipt or confirmation of delivery
is obtained), sent by Federal Express or other recognized overnight delivery
service, mailed by first-class, registered or certified mail, return receipt
requested, postage prepaid, or transmitted by facsimile transmission (followed
by delivery of the original of such document), addressed as set forth below.
Either party hereto may designate by notice, in the manner herein above
provided, a new address to which any notice, demand, request or communication
may thereafter be so given, served or sent. Each notice, demand, request or
communication which shall be mailed, delivered, or transmitted in the manner
described above shall be deemed sufficiently given, served, sent and received
for all purposes at such time as it is delivered to the addressee (with the
return receipt, the delivery receipt, the affidavit of messenger or (with
respect to a facsimile transmission) the answer back being deemed conclusive
evidence of such delivery) or at such time as delivery is refused by the
addressee upon presentation.Any notice or other communications under this
Agreement shall be in writing, signed by the party making the same, and shall be
delivered personally or sent by certified or registered mail, postage prepaid,
addressed as follows:

     If to Employee: Herbert Y. Wong
                     740 Polo Club Drive
                     Austin, Texas 78737

     If to Employer: Bridgetech Holdings International, Inc.
                     26th Floor
                     402 W. Broadway
                     San Diego, California 92101
                     Attention: Chief Executive Officer
                     Facsimile: (619) 342-7440

     15. GOVERNING LAW. This Agreement shall be interpreted and enforced in
accordance with the laws of the State of Texas.

     16. SEVERABILITY. The parties agree that construction of this Agreement
shall be in favor of its reasonable nature, legality and enforceability, and
that any construction causing unenforceability shall yield to a construction
permitting enforceability. It is agreed that the noncompetition,
nonsolicitation, nondisclosure and nonhiring covenants and provisions of this
Agreement are severable, and that if any single covenant or provision or
multiple covenants or provisions should be found unenforceable, the entire
Agreement and remaining covenants and provisions shall not fail but shall be
construed and enforceable without any severed covenant or provision in
accordance with the tenor of this Agreement. The parties specifically agree that
no

                                       -6-

<PAGE>

covenant or provision of this Agreement shall be invalidated because of
overbreadth insofar as the parties acknowledge the scope of the covenants and
provisions contained herein to be reasonable and necessary for the protection of
Employer and not unduly restrictive upon Employee. However, should a court or
any other trier of fact or law determine not to enforce any covenant or
provision of this Agreement as written due to overbreadth, then the parties
agree that said covenant or provision shall be enforced to the extent
reasonable, with the court or such trier to make any necessary revisions to said
covenant or provision to permit its enforceability, whether said revisions be in
time, territory, or scope of prohibited activities.

     17. ENTIRE AGREEMENT. This Agreement contains the entire agreement of the
parties hereto with respect to the subject matter contained herein. There are no
restrictions, promises, covenants, or undertakings, other than those expressly
set forth herein. This Agreement supersedes all prior agreements and
understandings between the parties with respect to such subject matter. This
Agreement may not be changed except by a writing executed by the parties.

     18. HEADINGS. The headings contained herein are for convenience of
reference only and are not intended to define, limit, expand or describe the
scope or intent of any provision of this Agreement.

     19. COUNTERPARTS. This Agreement may be executed in any number or
counterparts, each of which shall be deemed a part of the same original.

     IN WITNESS WHEREOF, the undersigned have executed this Agreement under seal
as of the day and year first above written.

EMPLOYER:                               EMPLOYEE:

BRIDGETECH HOLDINGS
INTERNATIONAL, INC.

By: /s/ Thomas C. Kuhn III              /s/ Herbert Wong
    ---------------------------------   ----------------------------------------
Name: Thomas C. Kuhn III                HERBERT Y. WONG
Title: President and COO

                                       -7-

<PAGE>

                                   EXHIBIT "A"

                              RESTRICTED TERRITORY

                          The United States of America

                                   Exhibit "A"
                                   Page 1 of 1

<PAGE>

                                   EXHIBIT "B"

                                CHANGE OF CONTROL

For the purposes of this Agreement, a "Change of Control" shall mean a change in
control of Employer of a nature that would be required to be reported (assuming
such event has not been "previously reported") in response to Item 1(a) of a
Current Report on Form 8-K pursuant to Section 13 or 15(d) of the Exchange Act
of 1934 (the "Exchange Act"); provided that, without limitation, a Change in
Control shall also be deemed to have occurred at such time as:

          (A) Any "person" within the meaning of Section 14(d) of the Exchange
Act, other than Employer, a subsidiary, or any employee benefit plan(s)
sponsored by Employer or any subsidiary thereof, is or has become the
"beneficial owner," as defined in Rule 13d-3 under the Exchange Act, directly or
indirectly, of fifty percent (50%) or more of the combined voting power of the
outstanding securities of Employer ordinarily having the right to vote at the
election of directors; or

          (B) Individuals who constitute the Board immediately prior to any
meeting of stockholders (the "Incumbent Board") have ceased for any reason to
constitute at least a majority thereof, provided that any person becoming a
director whose election, or nomination for election by Employer's stockholders,
was approved by a vote of at least three-quarters (3/4) of the directors
comprising the Incumbent Board (either by a specific vote or by approval of the
proxy statement of Employer in which such person is named as a nominee for
director without objection to such nomination) shall be, for purposes of this
Agreement, considered as though such person were a member of the Incumbent
Board; or

          (C) Upon approval by Employer's stockholders of a reorganization,
merger, share exchange or consolidation, other than one with respect to which
those persons who were the beneficial owners, immediately prior to such
reorganization, merger, share exchange or consolidation, of outstanding
securities of Employer ordinarily having the right to vote in the election of
directors own, immediately after such transaction, more than fifty percent (50%)
of the outstanding securities of the resulting corporation ordinarily having the
right to vote in the election of directors; or

          (D) Upon approval by Employer's stockholders of a complete liquidation
and dissolution of Employer or the sale or other disposition of all or
substantially all of the assets of Employer other than to a subsidiary thereof.

                                   Exhibit "B"
                                   Page 1 of 1<PAGE>

                                                                   EXHIBIT 10.17

                                LETTER OF INTENT

                                     FOR THE

             THE DEVELOPMENT OF A CLINICAL TRIAL CENTER IN HONG KONG

Among:

THE CHINESE UNIVERSITY OF HONG KONG, a university established by Ordinance in
the Hong Kong Special Administrative Region, at Shatin, New Territories, Hong
Kong SAR, China ("CUHK")

and,

BRIDGETECH HOLDINGS INTERNATIONAL, INC. a corporation whose registered office is
at Emerald Plaza Center, 402 Broadway, 26th Floor, San Diego, CA 92101,
U.S.A.("Bridgetech")

and,

BRIDGETECH MEDICAL TECHNOLOGIES RESEARCH & DEVELOPMENT LIMITED, a company whose
registered office is at Unit 2401-02, 24/F Admiralty Centre II, 18 Harcourt
Road, Admiralty, Hong Kong SAR, China ("BMT R&D").

I.   PURPOSE OF THE LOI

Bridgetech is working with a business model that will leverage its extensive
network of relationships in the US and China to capitalize on the demand for
Western Healthcare in China. Bridgetech, through BMT R&D is bringing emerging
drugs, devices and diagnostics to China, with an initial focus on Oncology and
Women's Health. Bridgetech would like to leverage on the expertise and track
record of CUHK by inviting CUHK to become a shareholder of BMT R&D.

CUHK welcomes this strategic alliance as new drugs and devices would be
introduced by BMT R&D to CHUK clinical investigators for potential participation
in trials and may stimulate new innovative research at CUHK.

II.  BACKGROUND OF THE PARTIES

Bridgetech is a publicly listed company (Symbol: BGTH.PK) in the United States.
In addition to the China healthcare market, Bridgetech is focusing on the areas
of medical imaging and non-invasive surgery, nurse recruitment and train, and
radio frequency identification (RFID) based hospital asset management.
Bridgetech has secured valuable domestic partnerships with MD Anderson, Mary
Crowley Medical Research Center, Vanderbilt University, Texas A&M

<PAGE>

University and others that will supply drugs, devices and diagnostics to run
through the business in China.

The major stock holders of the company include:

     -    HERBERT WONG, PH.D. - Chairman of the Board. Dr. Wong brings more than
          20 years of diversified executive leadership in healthcare to
          bridgetech. He is the former SVP and Chief Strategist for Columbia/HCA
          (revenue of US$22 billion) and the Founder and Executive Chairman of
          the United Premier Medical Group of Hong Kong.

     -    MICHAEL CHERMAK - President & CEO. Mr. Chermak has more than 25 years
          of healthcare industry experience with extensive expertise in
          establishing and leading start-up companies to success. He was the
          Founder and CEO of Healthdemographics, which he successfully sold in
          1998 as well ad the founder of Medibuy.com.

     -    THOMAS C. KUHN III - Chef Financial Officer (CFO). Mr. Kuhn has more
          than 21 years of financial experience and is a certified public
          accountant. He has held CFO positions at public and private companies
          and has extensive acquisition and strategic partnership expertise.
          Throughout his 20 year career, Mr. Kuhn has worked with both Fortune
          200 as well s high-growth start-up companies and has also served as a
          public accountant with Ernst and Young.

BMT R&D

BMT R&D is a Contract Research Organization (CRO) that provides professional
statistical and data management services with networks of centres in China and
Asia for Bridgetech and other industry to carry out multi-centre clinical trials
and facilitate drugs and devices development in Asia. BMT R&D is partnering and
collaborating with Johns Hopkins University, Vanderbilt Medical Centre, Mary
Crowley Foundation, and Amcare Labs International, and other biotechnology
companies in USA. BMT R&D will bring new drugs and devices developed from these
and other Institutions to the Asian market. The services to be provided by BMT
R&D include site selection and identification of qualified investigators, trial
design, protocol development, case-report form development, contract
negotiation, applications of ethics approval, clinical trial certificate, import
license, and to fulfill other regulatory requirements, monitoring and auditing
for clinical trials, computing services, statistical services and the
organization of Data & Safety Monitoring Committee (DSMC) operation. The sites
for the clinical trials to be selected may include CUHK (in which case separate
agreements will be signed) and other organizations in Hong Kong and China.

THE CENTRE FOR CLINICAL TRIALS (CCT) OF CUHK

CCT, established in 2003, is uniquely positioned to take advantage of the global
trend of clinical drug trials development in Asia. CCT will be an ideal
operating unit of CUHK for the alliance of BMT R&D. CUHK has built a reputation
among the pharmaceutical and biotech companies for reliable and prompt patient
recruitment into clinical trials. CCT is a Site Management Organization
providing professional statistical and data management services with strong

                                        2

<PAGE>

networks of centres in China and Asia for both academic and industries to carry
out multi-centre clinical trials and facilitate the drug and device development
process in Asia.

CCT is experienced in statistical consultation, clinical trials development,
management of Data & Safety Monitoring Committee (DSMC) operation, and provides
monitoring and auditing services. CCT also provides training and workshops for
good clinical practice (GCP), ethics, and research in Traditional Chinese
Medicine for Hospital Authority investigators, personnel from companies and
various departments within CUHK. CCT has developed an information technology
system for web-based applications to handle clinical trials operation, and has
contracts with pharmaceutical and biotechnology companies for data management.
CCT is unique in that is has strong biostatistics research background and an
understanding of the concerns among researchers, institutions and industry. CCT
has provided biostatistics consultations for the US. Canadian and European
pharmaceutical companies in drug development (e.g. Novartis, Pharmacia,
AstraZeneca, Biomira, Lorus, Cellular Bioengineering Co.).

INVESTIGATORS FROM CLINICAL CENTRES

Multi-centre clinical trials will be proposed by companies that produce new
products ("the Sponsor"). For such trials which will be managed by BMT R&D,
Clinical Centres including major hospitals in China and Hong Kong will be
approached by BMT R&D. Separate contracts and agreements between the Sponsors
and the individual institution of the investigators will be established for each
individual project. BMT R&D will only act as CRO to carry out data management
and to take up the project management role.

III. SCALE OF BMT R&D:

BMT R&D will establish the company by 3 phases:

<TABLE>
<CAPTION>
                                                            ESTIMATED INVESTMENT
PHASE                         SCOPE                              REQUIREMENT
-----                         -----                         --------------------
<S>     <c>                                                 <C>
I.      Establish an office in Hong Kong and run a few          HK$3,500,000
        trials in CUHK and hospitals in Hong Kong.

II.     Register BMT R&D in China and start introduce           HK$2,500,000
        trials to investigators of a few major clinical
        centres (Guangzhou, Beijing, Shanghai) in China
        for SFDA approval.

III.    Expansion to other investigators of clinical            HK$2,500,000
        centres in China

        ESTIMATED TOTAL INVESTMENT                              HK$8,500,000
</TABLE>

BMT R&D will fund the estimated total investment of HK $8.5 million partly by
equity investment and partly by loan financing.

                                        3

<PAGE>

IV.  OFFER TO THE CUHK:

In recognition of

     -    The reputation and expertise of CUHK and its personnel and

     -    The facilitation by CUHK of access to experts for the conduction of
          clinical trials, whether within or outside of CUHK

     -    The facilitation by CUHK of access to the CUHK resources necessary for
          the successful conduct of the trials and

     -    The facilitation by CUHK of access to an extensive network of
          collaborators in China,

BMT R&D will allot and issue to CUHK, free from any encumbrances and free of any
costs (including the price of the shares) charges or levies to CUHK, shares
(fully paid-up and with the rights to vote and receive dividends and other
distributions) amounting to 49% of the initial equity capital of BMT R&D.

CUHK will be entitled to additional free paid-up shares to maintain its 49%
interest in BMT R&D up to a maximum BMT R&D's equity capital of HK$8.5 million
in par value of the shares of BMT R&D. A right of first refusal to acquire
additional shares up to a total holding of 49% of the issued and paid-up shares
in BMT R&D will also be granted to CUHK.

V.   USE OF PARTNER ASSETS:

It is understood that any secondment of personnel by any party, for part-time
employment or consultancy or full-time employment, or any use of facilities or
premises will be on commercial compensation terms to be separately agreed and
contracted on a case by case basis. Similarly, any use of any registered
proprietary intellectual property will be subject to specific agreement upon the
payment of licensing fees or royalties. More specifically, BMT R&D will pay to
CUHK or to CUHK staff in their individual capacities (in which case permission
by CUHK for Outside Practice will be sought), by separate contracts, for the
following services:

          -    The service of Prof. Benny Chung-Ying Zee

          -    Supply of personnel to manage the day to day operation of BMT R&D

          -    Supply of personnel required for the operation of BMT R&D

          -    Oversight of the data collection and management of the trials

          -    Introduction of third party projects to be done on a fee for
               service basis

          -    Space for housing additional personnel hired by BMT R&D

                                        4

<PAGE>

          -    Existing computing resources and IT equipments of CCT

It is estimated that the charges for the above services and facilities will be
approximately HK $8.5 million for the first 3 years of engagement.

For the avoidance of doubt, any CUHK personnel engaged in these duties will,
unless otherwise agreed in writing, participate in their individual capacities
on Outside Practice terms approved by CUHK, and CUHK as an institution shall not
assume responsibility for the management or operation of BMT R&D.

VI.  MEDICAL AND ETHICAL STANDARD

     -    BMT R&D will comply with ethical standard as set forth by the Joint
          CUHK-NTEC Clinical Research Ethics Committee (CREC). CREC is a formal
          Ethics Committee endorsed by CUHK and the New Territories East Cluster
          of the Hospital Authority with clear standard operating procedure to
          ensure patients' right (http://www.crec.cuhk.edu.hk/)

     -    It is understood that while the Board of Directors of BMT R&D will
          have the overall responsibility for the commercial management of BMT
          R&D, matters of a medical and ethical nature will be approved by the
          CREC.

VII. INSURANCE COVERAGE

BMT R&D will have in place the following insurance coverage of the company which
will accord appropriate protection to the Company, including but not limited to
its personnel, shareholders and contractors:

-    General Liability Policy

-    Errors and Omissions Policy

VIII. CORPORATE BRANDS, ROYALTIES, INTELLECTUAL PROPERTY RIGHTS

BMT R&D will have full entitlement to all brands, inventions, patents and
intellectual property rights which are directly developed with resources
provided by BMT R&D and be eligible to receive all royalties and payments by
third parties making use of such developed tangible and intangible assets.

IX.  COSTS

Each party will bear its own cots when preparing for the definitive agreements
for this project and conducting further discussions.

                                        5

<PAGE>

This Letter of Intent is not legally binding on the parties but serves to form
the basis for further discussion and documentation. The parties intend to enter
into binding definitive agreements with terms similar the above-mentioned within
3 months of the signing of this Letter of Intent.

                                        6

<PAGE>

Failure to do so without further arrangement being made will result in the
expiry of this Letter of Intent.

Signed this 1st day of March, 2006 in Hong Kong SAR.

For and on behalf of                    For and on behalf of

The Chinese University of Hong Kong     Bridgetech Medical Technologies
                                        Research & Development Limited

/s/ Ngan Alice Man Wai                  Name: /s/ Thomas C. Kuhn
---------------------------                   ----------------------------------
Name: Ngan Alice Man Wai (Ms)           Title: Director
Title: Director, Research and
       Technology Administration
       Office

For and on behalf of

Bridgetech Holdings International, Inc.

Name: /s/ Thomas C. Kuhn III
      -------------------------------
Title: President

                                        7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]